Date: 2016-12-15
Type of information: Private placement
Company: Valneva (France - Austria)
Investors: MVM Life Science Partners (UK)
Amount: €7.5 million
Funding type: private placement
Planned used:
Others: * On December 15, 2016, Valneva announced that the share issuance in connection with MVM Life Science The placement resulted in aggregate proceeds of €7.5 million for Valneva. The total number of ordinary shares has increased to 77,582,714. Together with the purchase of a further tranche of shares from undisclosed shareholders of the Company, which is in the process of being closed, funds managed by MVM will own 7.5% of Valneva’s ordinary share capital.
Partners investment in the Company has closed. MVM’s investment consists of a combined purchase of new shares together with a tranche of shares from existing undisclosed shareholders of the Company. The transaction was announced on December 1. Valneva has now completed the issuance of 2,884,615 new ordinary shares to funds managed by MVM by way of a private placement without preferential subscription rights, based on resolution 24 of the June 2016 AGM and corresponding to a 3.9% dilution of the ordinary share capital.
Therapeutic area: Infectious diseases - Veterinary medicine - Technology - Services
